Skip to main content

23-02-2022 | ASCO GU 2022 | Conference coverage | Video

MAGNITUDE shows benefit of add-on niraparib for mutated mCRPC

Gerhardt Attard tells us why he is excited about the results of the MAGNITUDE trial evaluating the upfront addition of niraparib to abiraterone acetate in men with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations (5:11).